Clinical Trial Update: Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 trial update describes BuEAM conditioning with busulfan, etoposide, cytarabine, and melphalan before autologous stem cell transplantation for T-cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer Cell Lymphoma
• Non-hodgkin Lymphoma
• T-cell Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• CYTARABINE (CYTARABINE)
• Etoposide (Etoposide)
• Melphalan (Melphalan)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Non-Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN